Patent Update: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Platelet-activating factor receptor antagonists
- 1 July 1995
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 5 (7) , 653-672
- https://doi.org/10.1517/13543776.5.7.653
Abstract
Platelet-activating factor (PAF) has been implicated in a range of inflammatory conditions and an appropriate antagonist should prove to be a useful therapeutic agent. Although PAF antagonists have yet to be commercialised, a number are undergoing clinical trials. In disease states such as asthma there is evidence for the involvement of a variety of inflammatory mediators and the recent literature describes a variety of approaches to incorporating more than one mode of action in a single compound. This review is primarily an update on PAF antagonist patent publications for the period July 1993 to February 1995. Reference has been made to earlier compounds to provide an update on clinical progress and for comparison with newer antagonists.This publication has 65 references indexed in Scilit:
- Antitumor Activity of 5-Aryl-2,3-dihydroimidazo[2,1-a]isoquinolinesJournal of Medicinal Chemistry, 1995
- 3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a Novel Series of Platelet Activating Factor AntagonistsJournal of Medicinal Chemistry, 1994
- Comparison of 1-O-alkyl-, 1-O-alk-1'-enyl-, and 1-O-acyl-2-acetyl-sn-glycero-3-phosphoethanolamines and -3-phosphocholines as agonists of the platelet-activating factor familyBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Platelet-aggregating effects of platelet-activating factor-like phosphollpids formed by oxidation of phosphatidylcholines containing an sn-2-polyunsaturated fatty acyl groupBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Synthesis and Platelet-Activating Factor (PAF)-Antagonistic Activities of Trisubstituted Piperazine Derivatives.CHEMICAL & PHARMACEUTICAL BULLETIN, 1994
- Synthesis and Platelet-Activating Factor (PAF)-Antagonistic Activities of 1,4-Disubstituted Piperazine Derivatives.CHEMICAL & PHARMACEUTICAL BULLETIN, 1994
- THE EFFECT OF THE PLATELET-ACTIVATING FACTOR INHIBITOR TCV-309 ON REPERFUSION INJURY IN A CANINE MODEL OF ISCHEMIC LUNGTransplantation, 1993
- PLATELET-ACTIVATING FACTOR IN HEPATIC ISCHEMIA/REPERFUSION INJURYTransplantation, 1993
- Formation of platelet-activating factor-like phospholipids by Fe2+/ascorbate/EDTA-induced lipid peroxidationBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3-hydroxypropoxy)-phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate esterJournal of Medicinal Chemistry, 1992